Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

HIMS's multi-pronged build-out (AI, preventive care and peptides) is starting to work together, and the FDA peptide advi

Sources (1)

HIMS's multi-pronged build-out (AI, preventive care and peptides) is starting to work together, and the FDA peptide advisory committee review on 23-24 Jul is the key near-term catalyst. The share price has already caught up with the analyst consensus target, so further upside depends on Q2 data or progress on peptides.

Analyst consensus

The consensus analyst price target is about $27-28. The current price has largely caught up with it, so further upside needs to be driven by Q2 data or progress on peptides.

Key insights

Date

2026-06-05

Detail

WeightWatchers Med+ offers GLP-1 drugs through Eli Lilly's LillyDirect platform, with behavioural coaching, nutrition management and clinical support. It adds to the competition on several fronts alongside Amazon Pharmacy and Ro, but WW is positioned more as support for behavioural intervention. It stays away from compounded drugs, peptides and diagnostic testing, which leaves room to differentiate from HIMS's full-stack platform.

Item

WeightWatchers Med+ plugs into LillyDirect

Date

2026-06-05

Detail

The CEO said on X that Anthropic's AI is transformative for population health. Taken together with the launch of Labs AI (AI pattern recognition across 130+ biomarkers) and the remit of the new CMO Vinjamoori, which covers peptide therapies and longevity medicine, management is integrating the three lines of AI, preventive care and peptides.

Item

CEO Dudum publicly backs Anthropic's AI

Date

2026-06-05

Detail

Canaccord Genuity estimates the total addressable market (TAM) for non-GLP-1 compounded peptides at about $20 billion over 3-5 years. Every 1% of share HIMS captures equals $200 million of incremental revenue. Its competitive advantages: the 2025 acquisition of a US peptide manufacturing facility, a 1 million square foot 503A compounding site, and brand trust.

Item

Canaccord sizes the peptide market opportunity

Peptide catalyst

The FDA peptide advisory committee will review 12 peptides (including BPC-157 and TB-500) on 23-24 Jul, the most important near-term catalyst.

Price action

Closed at $28.01 on 5 Jun (up 2%), a second positive week in a row. On 6 Jun US stocks fell sharply (the Dow down 1.2% and semiconductors hit hard) and HIMS slipped about 1% after hours, but overall it is still holding steady in a $25-30 range.

Sources 1

  1. LillyDirect / Dudum X post / Canaccord Genuity via TIKR / market data

A brief is a lead for our research, not a verified conclusion or advice.